Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma ( LNH 03-1 B )
暂无分享,去创建一个
er | O. Casasnovas | H. Tilly | C. Haioun | T. Connerotte | C. Récher | C. Soussain | B. Christian | F. Morschhauser | C. Fruchart | C. Thieblemont | R. Delarue | J. Brière | B. Fabiani | D. Bordessoule | C. Bonnet | B. Anglaret | N. Ketterer | S. Bologna | C. Fermé | B. Coif
[1] T. Molina,et al. A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B , 2010 .
[2] N. Schmitz,et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) , 2008 .
[3] L. Rimsza,et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Molina,et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Gascoyne,et al. Clinical Trials and Observations , 2005 .
[6] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[7] L. Staudt,et al. Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation. , 2005 .
[8] T. Molina,et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.
[9] J. Earle,et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[11] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Fisher,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.
[13] J. Connors,et al. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. , 1987, Annals of internal medicine.
[14] J. Kinzie,et al. Survival of patients with localized diffuse histiocytic lymphoma. , 1981, Blood.
[15] E. Freireich,et al. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types , 1980, Cancer.